3 papers in the library · publishing 2024-2026
American Journal of Therapeutics February 20, 2026 Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al.
Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.
Dialogues in Clinical Neuroscience September 2, 2024 Shiven Chaudhry, Anne Weisman, Molly M. Hagen et al.
INTRODUCTION: This study evaluates the impact of a two-hour team-based learning (TBL) curriculum on medical students' knowledge, comprehension, ethical understanding, and attitudes towards psychedelic therapies. METHODS: Sixty-three pre-surveys and fifty post-surveys assessed students' perceived knowledge and attitudes using Likert scales. Forty-eight matched pre/post-knowledge tests with...
Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al. preprint
Background: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as Mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad (Incilius alvarius) and various plant species. Areas of Uncertainty: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiological role remains unclear. Safety profiles...